ACTI.ST announces 1-for-100 reverse split for 2026-06-03Active Biotech AB (publ)（ACTI.ST）宣布 1:100 合股，生效日 2026-06-03

Corporate Action

ACTI.ST, the ticker for Swedish biotechnology firm Active Biotech AB (publ), implemented a 1-for-100 reverse stock split on June 3, 2026. This nominal equity adjustment impacts trading mechanics, index eligibility, and retail investor access, making it a critical data point for market participants tracking the security.

Mechanical Impact

The reverse split follows a strict 1:100 ratio: every 100 outstanding common shares will be exchanged for 1 new share. Following the split, the company’s total outstanding share count will be reduced to 1% of its pre-split level, and the per-share trading price will adjust to 100 times the pre-split price. The split itself does not alter the company’s total market capitalization, as total market value equals per-share price multiplied by total outstanding shares, with the two adjustments fully offsetting one another without creating incremental value.

Signal Interpretation

Reverse stock splits are commonly implemented to meet minimum share price listing requirements set by stock exchanges, or to address low per-share pricing that may create retail investor access barriers, reduce liquidity, or trigger delisting risks. For ACTI.ST, the specific rationale for this split will require cross-referencing with exchange rules, but the action only modifies the nominal equity structure without substantive changes to business or financial operations.

What This Signal Does Not Prove

This reverse split does not signal any improvement in the company’s underlying fundamentals, including clinical trial progress, revenue growth, or profitability. The split alone cannot be used as evidence of improved operational or financial performance, and no additional data links this action to changes in the company’s core business metrics.